Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6GLX

Structure of galectin-10 in complex with the Fab fragment of a Charcot-Leyden crystal solubilizing antibody, 4E8

Summary for 6GLX
Entry DOI10.2210/pdb6glx/pdb
DescriptorGalectin-10, Fab 4E8 - Heavy chain, Fab 4E8 - Light chain (3 entities in total)
Functional Keywordsfab, galectin-10, autocrystallizing, crystal solubilisation, sugar binding protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains6
Total formula weight136023.01
Authors
Verstraete, K.,Verschueren, K.,Savvides, S.N. (deposition date: 2018-05-23, release date: 2019-06-05, Last modification date: 2024-01-17)
Primary citationPersson, E.K.,Verstraete, K.,Heyndrickx, I.,Gevaert, E.,Aegerter, H.,Percier, J.M.,Deswarte, K.,Verschueren, K.H.G.,Dansercoer, A.,Gras, D.,Chanez, P.,Bachert, C.,Goncalves, A.,Van Gorp, H.,De Haard, H.,Blanchetot, C.,Saunders, M.,Hammad, H.,Savvides, S.N.,Lambrecht, B.N.
Protein crystallization promotes type 2 immunity and is reversible by antibody treatment.
Science, 364:-, 2019
Cited by
PubMed Abstract: Although spontaneous protein crystallization is a rare event in vivo, Charcot-Leyden crystals (CLCs) consisting of galectin-10 (Gal10) protein are frequently observed in eosinophilic diseases, such as asthma. We found that CLCs derived from patients showed crystal packing and Gal10 structure identical to those of Gal10 crystals grown in vitro. When administered to the airways, crystalline Gal10 stimulated innate and adaptive immunity and acted as a type 2 adjuvant. By contrast, a soluble Gal10 mutein was inert. Antibodies directed against key epitopes of the CLC crystallization interface dissolved preexisting CLCs in patient-derived mucus within hours and reversed crystal-driven inflammation, goblet-cell metaplasia, immunoglobulin E (IgE) synthesis, and bronchial hyperreactivity (BHR) in a humanized mouse model of asthma. Thus, protein crystals may promote hallmark features of asthma and are targetable by crystal-dissolving antibodies.
PubMed: 31123109
DOI: 10.1126/science.aaw4295
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.396 Å)
Structure validation

226707

数据于2024-10-30公开中

PDB statisticsPDBj update infoContact PDBjnumon